All In Biotech

Drug Trial Radar · NCT05384119

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

REVERT- Breast Cancer: Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance to Palbociclib or Ribociclib Plus Aromatase Inhibitor or Fulvestrant Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

6

Actual

Start

Jan 9, 2023

Primary completion

May 6, 2024

Study completion May 6, 2024

Sponsor

Sponsor type
Industry
Collaborators
National Cancer Institute (NCI)
First posted
May 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of Phase 1b will be to evaluate the safety and tolerability of TTI-101 when added to palbociclib and AI or fulvestrant administered orally to participants with hormone receptor-positive (HR+) human epidermal receptor 2-negative (HER2)- palbociclib-resistant breast cancer, and to determine the recommended Phase 2 dose (RP2D) for TTI-101 when added to palbociclib and AI or fulvestrant. The primary objective of Phase 2 will be to evaluate anti-tumor activity in participants who receive TTI-101 added to palbociclib or ribociclib and AI or fulvestrant.

Conditions

  • Breast Cancer

Interventions

  • TTI-101Drug

    Oral tablet

  • PalbociclibDrug

    Oral capsule

  • Aromatase inhibitor (AI)Drug

    Oral tablet

  • fulvestrantDrug

    Oral tablet

  • ribociclibDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Time frame: Day 1 to Day 28
  2. Phase 1b: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 17 months
  3. Phase 1b: Number of Participants Who Experience a Serious Adverse Event (SAE)Time frame: Up to approximately 17 months
  4. Phase 2: Landmark Progression Free Survival at 6 Months (PFS6)Time frame: 6 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Holy Cross Health Fort Lauderdale - Holy Cross Hospital

    Fort Lauderdale, Florida

  • Washington University School of Medicine Siteman Cancer Center

    St Louis, Missouri

  • Vanderbilt - Ingram Cancer Center

    Nashville, Tennessee

  • Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • Harold C. Simmons Comprehensive Cancer Center

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.